This project will extend the principal investigator's basic and clinical research on regulation of blood coagulation involving studies of protein-protein and protein-lipid interactions and on translational clinical research studies of venous thrombosis risk factors. Thrombosis is strongly linked to failure to regulate thrombin generation, i.e., to an imbalance in anticoagulant and procoagulant mechanisms. One major goal of this project is to elucidate molecular interactions that are critical for thrombin generation. We hypothesize that molecular mechanisms for regulation of thrombin generation by the blood coagulation pathways are determined by specific amino acids on surfaces of coagulation factors V (fV) and X (fX) and by specific lipids that determine the assembly of the procoagulant prothrombinase complex (fXa:fVa:phospholipid:Ca++). Preliminary data from synthetic peptides that inhibit fVa or fXa functions combined with analysis of fVa and fXa three-dimensional structures enable us to propose specific mutations in fVa and fXa that we speculate will cause loss of functional activities.
In specific aims 1 -4, the fVa and fXa mutants will be studied using coagulation and prothrombinase assays and fluorescence spectroscopy to identify dysfunctional molecules and to characterize the nature of their dysfunction. Based on preliminary data showing that sphingosine and other long chain alkyl amines are potent anticoagulants, we propose to clarify how sphingosine inhibits thrombin generation by neutralizing the prothrombinase complex activity. A second major goal involves translational thrombosis research. As in the previous period of support, we propose continued studies that build a bridge between plasma dyslipoproteinemia research and blood coagulation research. Based on preliminary data, we propose studies to test the hypothesis that risk of excessive thrombin generation in vivo, manifested as venous thrombosis, is associated with HDL2b deficiency and that this is caused by genetic variations (SNPs) in genes that regulate lipoprotein and HDL metabolism. The proposed studies will increase our insights into the pathophysiology of thrombosis and are likely to improve diagnosis and treatment of thrombosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL021544-28
Application #
6823618
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Link, Rebecca P
Project Start
1992-07-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
28
Fiscal Year
2004
Total Cost
$469,250
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Deguchi, Hiroshi; Elias, Darlene J; Griffin, John H (2017) Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. Res Pract Thromb Haemost 1:93-102
Deguchi, Hiroshi; Navarro, Silvia; Payne, Amanda B et al. (2017) Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. Res Pract Thromb Haemost 1:33-40
Alsultan, Abdulrahman; Gale, Andrew J; Kurban, Kadijah et al. (2016) Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis. Thromb Res 143:17-21
Griffin, John H; Fernández, José A; Lyden, Patrick D et al. (2016) Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. Thromb Res 141 Suppl 2:S62-4
Deguchi, Hiroshi; Banerjee, Yajnavalka; Elias, Darlene J et al. (2016) Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. J Atheroscler Thromb 23:1159-1167
Deguchi, Hiroshi; Sinha, Ranjeet K; Marchese, Patrizia et al. (2016) Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood 128:1870-1878
Gale, Andrew J; Bhat, Vikas; Pellequer, Jean-Luc et al. (2016) Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. Pharm Res 33:1517-26
Sinha, Ranjeet K; Yang, Xia V; Fernández, José A et al. (2016) Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization. Arterioscler Thromb Vasc Biol 36:518-24
Wang, Yaoming; Zhao, Zhen; Rege, Sanket V et al. (2016) 3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. Nat Med 22:1050-5
Banno, Fumiaki; Kita, Toshiyuki; Fernández, José A et al. (2015) Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. Blood 126:2247-53

Showing the most recent 10 out of 139 publications